Latest News and Press Releases
Want to stay updated on the latest news?
-
MIAMI BEACH, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new...
-
ALCESTER, United Kingdom and BEVERLY, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for...
-
SANTA ROSA, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vintage Wine Estates, Inc. (NASDAQ: VWE) (TSX: VWE.U) (TSX: VWE.WT.U) (“VWE” or the “Company”), one of the fastest growing wine producers in the...
-
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment...
-
THE WOODLANDS, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3...
-
-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform- -Reported topline data from SEL-399 (empty AAV8 capsid in...
-
RESTON, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that it received a Notice of Allowance for a key...
-
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
-
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rosebud Woman, the leader in women's intimate skin and body care, launches a focused product assortment today on Maisonette, the expertly curated...
-
Data Suggest that ONC-392 Monotherapy has Promising Anti-tumor Activity in Stage IV Cancer Patients Who Have Failed Multiple Lines of Prior Therapy Company Plans to advance into Phase II/III studies ...